Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Drug-induced hyperthermia in Huntington's disease.

Gaasbeek D, Naarding P, Stor T, Kremer HP.

J Neurol. 2004 Apr;251(4):454-7.

PMID:
15083292
2.

Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.

Mateo D, Muñoz-Blanco JL, Giménez-Roldán S.

Clin Neuropharmacol. 1992 Feb;15(1):63-8.

PMID:
1533561
3.

Progression of symptoms in neuroleptic malignant syndrome.

Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE.

J Nerv Ment Dis. 1994 Mar;182(3):168-73.

PMID:
7906709
4.

Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.

Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH.

Neurology. 1981 Aug;31(8):1022-5.

PMID:
6115336
5.

[Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].

Khaldi S, Kornreich C, Choubani Z, Gourevitch R.

Encephale. 2008 Dec;34(6):618-24. doi: 10.1016/j.encep.2007.11.007. Epub 2008 Apr 2. Review. French.

PMID:
19081460
6.

Adverse drug reactions resulting in hyperthermia in the intensive care unit.

McAllen KJ, Schwartz DR.

Crit Care Med. 2010 Jun;38(6 Suppl):S244-52. doi: 10.1097/CCM.0b013e3181dda0d4. Review.

PMID:
20502177
7.
8.

[Malignant hyperthermia and neuroleptic malignant syndrome: report of 4 clinical cases].

Samuelian JC, Chabannes JM, Vedy P, Kozak-Reiss G.

Encephale. 1999 May-Jun;25(3):222-5. French.

PMID:
10434147
9.

Adverse effects of summer amongst people with learning disabilities: neuroleptic malignant syndrome.

Fitzgerald B, Middleton JK, Cooper SA.

J Intellect Disabil Res. 1997 Jun;41 ( Pt 3):273-7.

PMID:
9219078
10.

[Clinical picture and course of the neuroleptic malignant syndrome (acute febrile neuroleptic encephalopathy)].

Avrutskiĭ GIa, Raĭskiĭ VA, Tsygankov BD.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(9):1391-6. Russian.

PMID:
3425085
11.

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease.

Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A, et al.

Ann Neurol. 1989 Mar;25(3):252-9.

PMID:
2524992
12.

Neuroleptic malignant syndrome: recognizing an unrecognized killer.

Hooper JF, Herren CK, Goldwasser H.

J Psychosoc Nurs Ment Health Serv. 1989 Jul;27(7):13-5.

PMID:
2746556
13.

Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatients.

Shiloh R, Valevski A, Bodinger L, Misgav S, Aizenberg D, Dorfman-Etrog P, Weizman A, Munitz H.

Int Clin Psychopharmacol. 2003 May;18(3):147-9.

PMID:
12702893
14.

The evaluation and management of patients with neuroleptic malignant syndrome.

Bhanushali MJ, Tuite PJ.

Neurol Clin. 2004 May;22(2):389-411. Review.

PMID:
15062519
15.

Hypokinesia in Huntington's disease.

van Vugt JP, van Hilten BJ, Roos RA.

Mov Disord. 1996 Jul;11(4):384-8.

PMID:
8813217
16.

[Acute catatonic syndrome after neuroleptic malignant syndrome].

Benjelloun G, Jehel L, Abgrall G, Pelissolo A, Allilaire J.

Encephale. 2005 Nov-Dec;31(6 Pt 1):705-9. French.

PMID:
16462690
17.

Effect of piracetam in Huntington's chorea.

Destée A, Petit H, Warot P.

Eur Neurol. 1984;23(2):89-91.

PMID:
6233148
18.

Prevention, recognition, and management of serotonin syndrome.

Ables AZ, Nagubilli R.

Am Fam Physician. 2010 May 1;81(9):1139-42. Review.

19.

Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration.

Norris B, Angeles V, Eisenstein R, Seale JP.

Ann Pharmacother. 2006 Dec;40(12):2260-4. Epub 2006 Nov 21.

PMID:
17119106
20.

Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.

Nozaki I, Furukawa Y, Kato-Motozaki Y, Ikeda T, Tagami A, Takahashi K, Ishida C, Komai K.

Intern Med. 2014;53(11):1201-4. Epub 2014 Jun 1.

Supplemental Content

Support Center